Metabolites of Glutamate Metabolism Are Associated With Incident Cardiovascular Events in the PREDIMED PREvencion con DIeta MEDiterranea (PREDIMED) Trial
Background-Glutamate metabolism may play a role in the pathophysiology of cardiometabolic disorders. However, there is limited evidence of an association between glutamate-related metabolites and, moreover, changes in these metabolites, and risk of cardiovascular disease (CVD). Methods and Results-P...
| Autores: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2016 |
| País: | España |
| Institución: | Conselleria de Salut i Consum del Govern de les Illes Balears |
| Repositorio: | Docusalut |
| Idioma: | inglés |
| OAI Identifier: | oai:docusalut.com:20.500.13003/17180 |
| Acceso en línea: | https://hdl.handle.net/20.500.13003/17180 |
| Access Level: | acceso abierto |
| Palabra clave: | Risk Factors Aged Cardiovascular Diseases Diabetes Mellitus, Type 2 Aged, 80 and over Randomized Controlled Trials as Topic Spain Glutamine Humans Smoking Hypertension Middle Aged Stroke Myocardial Infarction Male Cholesterol, LDL Cholesterol, HDL Dyslipidemias Female Proportional Hazards Models Diet, Mediterranean Tobacco Smoking Glutamic Acid Incidence Hipertensión Dislipidemias Factores de Riesgo Dieta Mediterránea Incidencia Modelos de Riesgos Proporcionales Ácido Glutámico Accidente Cerebrovascular LDL-Colesterol Femenino Infarto del Miocardio Fumar Tabaco HDL-Colesterol Masculino Glutamina Fumar Enfermedades Cardiovasculares Ensayos Clínicos Controlados Aleatorios como Asunto España Diabetes Mellitus Tipo 2 Anciano de 80 o más Años Anciano Persona de Mediana Edad Humanos cardiovascular disease diet dietary clinical trial epidemiology glutamate glutamine incidence stroke |
| Sumario: | Background-Glutamate metabolism may play a role in the pathophysiology of cardiometabolic disorders. However, there is limited evidence of an association between glutamate-related metabolites and, moreover, changes in these metabolites, and risk of cardiovascular disease (CVD). Methods and Results-Plasma levels of glutamate and glutamine were measured at baseline and 1-year follow-up in a case-cohort study including 980 participants (mean age 68 years; 46% male) from the PREvencion con DIeta MEDiterranea (PREDIMED) randomized trial, which assessed a Mediterranean diet intervention in the primary prevention of CVD. During median 4.8 years of follow-up, there were 229 incident CVD events (nonfatal stroke, nonfatal myocardial infarction, or CVD death). In fully adjusted models, per 1-SD, baseline glutamate was associated with 43% (95% CI: 16% to 76%) and 81% (39% to 137%) increased risk of composite CVD and stroke alone, respectively, and baseline glutamine-to-glutamate ratio with 25% (6% to 40%) and 44% (25% to 58%) decreased risk of composite CVD and stroke alone, respectively. Associations appeared linear for stroke (both P-linear trend <= 0.005). Among participants with high baseline glutamate, the interventions lowered CVD risk by 37% compared to the control diet; the intervention effects were not significant when baseline glutamate was low (P-interaction=0.02). No significant effect of the intervention on year-1 changes in metabolites was observed, and no effect of changes themselves on CVD risk was apparent. Conclusions-Baseline glutamate was associated with increased CVD risk, particularly stroke, and glutamine-to-glutamate ratio was associated with decreased risk. Participants with high glutamate levels may obtain greater benefits from the Mediterranean diet than those with low levels. |
|---|